Insulin Gene Polymorphism and Prostate Cancer Risk
Author Information
Author(s): Ho G Y F, Melman A, Liu S-M, Li M, Yu H, Negassa A, Burk R D, Hsing A W, Ghavamian R, Chua S C Jr
Primary Institution: Albert Einstein College of Medicine
Hypothesis
Is there a relationship between the insulin gene polymorphism and the risk of prostate cancer?
Conclusion
The study found that the homozygous CC genotype of the +1127 INS-PstI marker is associated with an increased risk of prostate cancer.
Supporting Evidence
- Men with the homozygous CC genotype had a 1.74 odds ratio for prostate cancer compared to other genotypes.
- The association was stronger among nondiabetic subjects.
- Linkage disequilibrium was observed between the +1127 INS-PstI marker and other SNPs in the region.
Takeaway
This study suggests that a specific change in the insulin gene may make some men more likely to get prostate cancer.
Methodology
A case-control study was conducted with 191 prostate cancer cases and 148 controls, genotyping for three markers in the TH-INS-IGF2 region.
Potential Biases
Potential population stratification bias, especially among Hispanic participants.
Limitations
The study had a small sample size and lacked fasting blood samples to measure insulin levels.
Participant Demographics
The cases included 54% African Americans, 22% Caucasians, 21% Hispanics, and 3% others.
Statistical Information
P-Value
0.055
Confidence Interval
1.74 (0.99–3.05)
Statistical Significance
p=0.055
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website